Ficerafusp alfa
Based on 1 Customer Validation
Ficerafusp alfa (BCA-101; FMAB2) is a bifunctional antibody targeting EGFR and TGFβ, with a Kd of 2.58 nM for EGFR and a Kd value of 61.3 nM for TGFβ1. Ficerafusp alfa binds EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ through its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and induced regulatory T cell differentiation. Ficerafusp alfa can be used in research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer.
For research use only. We do not sell to patients.
- Purity : 99.71%
- CAS No.: 2764727-44-6
- Molecular Weight:178.105 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Description
Isotype
IgG1-kappa-[PROTEIN]2-in-VK
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
EGFR 2.58 nM (Kd) |
TGFβ1 61.3 nM (Kd) |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:56 nM
-
Incubation Time:120 hours
-
Result:Significantly reduced TGFβ-induced IL11 secretion, with IL11 concentrations lower than those in cetuximab and isotype control groups.\nSignificantly reduced IL11 secretion in A549 cells with established TGFβ-induced EMT, with IL11 concentrations lower than those in cetuximab and isotype control groups.
In Vivo
Ficerafusp alfa (50 mg/kg; i.p.; twice weekly) enhances the antitumor efficacy of anti-PD1 immunotherapy in a syngeneic melanoma model expressing human EGFR, conferring superior event-free survival compared with the monotherapy group[1].
Ficerafusp alfa (10 mg/kg; i.p.; twice weekly) acts synergistically with the Pembrolizumab (HY-P9902) monoclonal antibody, enhancing antitumor efficacy in a humanized prostate cancer xenograft model, with a TGI of 78% on day 18[1].
Ficerafusp alfa (10 mg/kg; intraperitoneal injection; 3 times per week; for 27 days) achieves sustained tumor growth delay in a head and neck squamous cell carcinoma PDX model in female NOG mice and neutralizes 90% of tumor TGFβ[3].
Ficerafusp alfa (intraperitoneal injection; 6 doses total) enhances the antitumor efficacy of PD-1 blockade therapy (Pembrolizumab, administered at 10 mg/kg once every 5 days for 5 doses total) in the PC-3 xenograft model in humanized Hu-NOG-EXL mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOG mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice a week; 27 days (PDX-1); 34 days (PDX-2); 32 days (PDX-3)
-
Result:In PDX-1, after 27 days of treatment and 52 days of follow-up, only 1 of 9 mice had tumor regrowth beyond initial 130 mm3 volume, compared with 6 of 10 mice in cetuximab group; mean tumor volume on day 79 was 67 mm3 vs. 146 mm3 for cetuximab.\nIn PDX-2, produced statistically significant lower mean tumor volume at treatment cessation (134 mm3 vs. 210 mm3 for cetuximab) and longer tumor doubling time (68 days vs. 47 days for cetuximab) after 34 days of treatment and 74 days of follow-up.\nIn PDX-3 (recurrent metastatic model), no tumors relapsed, compared with 2 of 10 mice in cetuximab group.
-
Animal Model:C57BL/6 mice[1]
-
Dosage:50 mg/kg (monotherapy; in combination with anti-PD1 mAb 10 mg/kg)
-
Administration:i.p.; twice a week
-
Result:As monotherapy, reduced the number of mice reaching a tumor volume ≥ 300 mm3 to 4 of 9, compared with 8 of 9 in the vehicle group.\nIn combination with anti-PD1 mAb, only 1 of 9 mice reached a tumor volume ≥ 300 mm3, superior to anti-PD1 monotherapy (3 of 9 mice) and cetuximab plus anti-PD1 combination (3 of 9 mice).\nThe combination produced a significant improvement in event-free survival (P=0.0034 vs. vehicle).
-
Animal Model:HuNOG-EXL humanized mice[1]
-
Dosage:10 mg/kg (monotherapy; in combination with pembrolizumab 10 mg/kg)
-
Administration:i.p.; twice a week
-
Result:As monotherapy, produced a 40% tumor growth inhibition (TGI) on day 18.\nIn combination with pembrolizumab, TGI increased to 78% on day 18, superior to the 52% TGI achieved with pembrolizumab monotherapy.\nAll treatments were associated with acceptable weight loss (≤ 15%).
- Somatic Cell Culture
- Cell Cytotoxicity Assay
- Organotypic 3D Invasion Assay
- Cell invasion
- Matrigel/ECM Transwell Invasion Assay
- MTT Cell Proliferation Assay
- iPSC cell differentiation
- 3D Collagen/Hydrogel Matrix Invasion Assay
- Spheroid/Tumor Organoid Invasion Assay
- Western Blot
- Ex Vivo Tissue Slice/Explant Invasion Assay
- Patient-Derived Organoid Invasion Assay
- Mammalian live/dead viability and cytotoxicity staining
- BrdU Incorporation Assay
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- 3D Tumor Spheroid Invasion Assay
- Research Protocol for Cancer Immunology
- Cell Viability Determination by MTT Colorimetric Assay
- Matrigel Transwell/Boyden Chamber Invasion Assay
- Kinase activity and phosphorylation assays
- Invadopodia/Fluorescent Gelatin Degradation Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Protocol for Kinase activity and phosphorylation assays
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa-[PROTEIN]2-in-VK
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized EGFR Protein, Human (621a.a, HEK293, His, HY-P70613) can bind Ficerafusp alfa. The EC50 for this effect is 8.521 ng/mL.
Chemical Information
-
CAS No. 2764727-44-6
-
Appearance Liquid
-
Molecular Weight 178.105 kDa
-
Color Colorless to light yellow
-
SMILES
[Ficerafusp alfa]
-
Synonyms
BCA-101; FMAB2
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Boreddy SR, et al. BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth. Cancer Res. 2023;83(11):1883-1904. [Content Brief]
[2]. Hernando-Calvo A, et al. Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors. Clin Cancer Res. 2025;31(22):4623-4632. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ficerafusp alfa Related Classifications
HY-P990957 Related Classifications
Powered by Bioz
Keywords
- Ficerafusp alfa
- 2764727-44-6
- BCA-101
- FMAB2
- BCA101
- BCA 101
- FMAB2
- FMAB 2
- FMAB-2
- EGFR
- TGF-β Receptor
- Epidermal growth factor receptor
- ErbB-1
- HER1
- Transforming growth factor beta receptors
- epithelial to mesenchymal transition
- TGFβ1
- TGFβ
- head and neck squamous cell carcinoma
- colorectal cancer
- A549 cells
- regulatory T cell
- squamous non-small cell lung cancer
- peripheral blood mononuclear cells
- Inhibitor
- inhibitor
- inhibit